证券代码：688217 证券简称：睿昂基因 公告编号：2024-032 上海睿昂基因科技股份有限公司 关于 2024 年第一季度计提及转回 资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、计提及转回减值准备情况概述 根据《企业会计准则》以及公司会计政策、会计估计的相关规定，为了真实、 准确地反映公司截至 2024 年 3 月 31 日的财务状况及 2024 年第一季度的经营成 果，本着谨慎性原则，对截至 2024 年 3 月 31 日公司及子公司相关信用及资产进 行了减值测试并计提了相应的减值准备。2024 年度第一季度公司拟计提各类信 用及转回资产减值准备共计 2,850,961.92 元。具体情况如下： 单位：元 | 项目 | 2024 年第一季度计提金额 | 备注 | | --- | --- | --- | | 信用减值损失 | 2,851,284.76 | 应收账款坏账损失、其他应收 款坏账损失、应收票据坏账损 | | | | 失 | | 资产减值损失 | -322.84 | 存货跌价损失转 ...

Financial Performance - The company's operating revenue for Q1 2024 was CNY 64,188,221.36, representing a year-on-year increase of 12.84%[4] - The net profit attributable to shareholders decreased by 58.70% to CNY 533,165.07 compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 142.08% to CNY -614,601.26[4] - Basic and diluted earnings per share were both CNY 0.01, down 50.00% year-on-year[5] - The total comprehensive income attributable to the parent company was ¥533,165.07, a decrease of 58.7% from ¥1,290,913.02 in Q1 2023[24] - Basic and diluted earnings per share were both ¥0.01, down from ¥0.02 in the same quarter last year[24] - The company reported a total comprehensive loss of -¥1,437,353.69 for the quarter, compared to a loss of -¥5,300,038.19 in Q1 2023[24] Cash Flow and Investments - The net cash flow from operating activities was CNY 11,518,866.49, a decline of 68.54% year-on-year[5] - In Q1 2024, the company reported a net cash flow from operating activities of ¥11,518,866.49, a decrease of 68.5% compared to ¥36,611,099.54 in Q1 2023[26] - The company experienced a net cash outflow from investing activities of ¥13,134,945.95, an improvement from a net outflow of ¥69,686,922.78 in Q1 2023[28] - The net cash flow from financing activities was -¥15,063,836.61, compared to -¥12,288.24 in the previous year, indicating increased cash outflows[28] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,026,567,072.49, a decrease of 1.68% from the end of the previous year[5] - The total assets as of Q1 2024 amounted to ¥1,026,567,072.49, a decrease from ¥1,044,159,929.12 in the previous year[20] - Total liabilities for Q1 2024 were ¥75,245,107.05, down from ¥76,484,453.94 in Q1 2023[21] - The total equity attributable to shareholders decreased to ¥931,393,288.97 in Q1 2024 from ¥945,776,279.95 in Q1 2023[21] Research and Development - Research and development expenses totaled CNY 16,398,202.66, accounting for 25.55% of operating revenue, an increase of 0.17 percentage points[5] - Research and development expenses increased to ¥16,398,202.66 in Q1 2024, compared to ¥14,436,134.44 in Q1 2023, marking a growth of 13.6%[23] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 4,233[11] - The company plans to repurchase shares with a total fund of no less than RMB 15 million and no more than RMB 20 million, with a maximum repurchase price of RMB 49.00 per share[16] - As of March 29, 2024, the company has repurchased a total of 578,305 shares, accounting for 1.04% of the total share capital, with a total payment of RMB 14,912,378.81[17] Cash and Cash Equivalents - The company's cash and cash equivalents as of March 31, 2024, amounted to RMB 145,081,494.73, compared to RMB 161,676,112.05 on December 31, 2023[18] - The company's cash and cash equivalents at the end of the period were ¥145,047,025.93, down from ¥163,445,523.02 at the end of Q1 2023[28] - The company's cash and cash equivalents increased to ¥82,407,860.90 in Q1 2024, compared to ¥72,363,081.39 in Q1 2023, reflecting a growth of 41.5%[19] Inventory and Accounts Receivable - The inventory level was reported at ¥59,944,143.00 in Q1 2024, slightly down from ¥60,654,837.57 in Q1 2023[19] - The company reported a decrease in accounts receivable to ¥183,424,651.56 in Q1 2024 from ¥187,232,001.40 in Q1 2023[19] Revenue from Sales - Total operating costs for Q1 2024 were ¥64,568,301.80, up from ¥60,723,636.64 in Q1 2023, reflecting a rise of 6.0%[22] - Total revenue from sales of goods and services was ¥57,158,250.16, down 47.3% from ¥108,321,178.65 in the same period last year[26]

证券代码：688217 证券简称：睿昂基因 公告编号：2024-031 上海睿昂基因科技股份有限公司 关于使用部分暂时闲置募集资金 进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资种类：安全性高、流动性好的理财产品（包括但不限于结构性存款、 定期存款、大额存单、通知存款、协定存款等）。 投资金额：上海睿昂基因科技股份有限公司（以下简称"公司"）及实施 募集资金投资项目（以下简称"募投项目"）的全资子公司（以下简称"子公司"） 拟使用合计不超过人民币 2,500 万元（含本数）的部分暂时闲置募集资金进行现 金管理，在上述额度内资金可以循环滚动使用。 投资期限：自上一次授权期限到期日（2024 年 6 月 25 日）起 12 个月内 有效。 履行的审议程序：公司于 2024 年 4 月 26 日召开了第二届董事会第二十 四次会议和第二届监事会第十八次会议，分别审议通过了《关于使用部分暂时闲 置募集资金进行现金管理的议案》，公司监事会就此事项发表了明确同意的意见， 保荐机构国泰君安证券股份 ...

证券代码：688217 证券简称：睿昂基因 公告编号：2024-030 上海睿昂基因科技股份有限公司（以下简称"公司"）第二届监事会第十八 次会议于 2024 年 4 月 26 日在公司会议室以现场结合通讯方式召开，本次会议已 于 2024 年 4 月 22 日以邮件方式发出会议通知。本次会议由监事会主席李云航先 生召集并主持，会议应出席监事 3 名，实际出席监事 3 名。本次会议的召集与召 开符合《中华人民共和国公司法》（以下简称"《公司法》"）等法律、法规、规范 性文件及《上海睿昂基因科技股份有限公司章程》（以下简称"《公司章程》"）的 相关规定，形成的决议合法有效。 二、监事会会议审议情况 经与会监事认真审议，形成如下决议： （一）审议通过《关于<2024 年第一季度报告>的议案》 公司监事会认为：公司《2024 年第一季度报告》的编制符合有关法律、法规、 规范性文件及《公司章程》、公司内部管理制度的规定，公司严格按照公司财务 制度规范运作，公司《2024 年第一季度报告》公允、全面、真实地反映了公司 2024 年第一季度的财务状况和经营成果等事项，披露的信息真实、准确、完整， 不存在任何虚假记载、误导 ...

证券代码：688217 证券简称：睿昂基因 5、公司有人工智能医疗相关的业务及技术吗？ 上海睿昂基因科技股份有限公司投资者关系活动记录表 编号：2024-03 投资者活动类 别 特定对象调研 分析师会议 媒体采访 业绩说明会 新闻发布会 路演活动 现场参观 其他 公司接待 成员名单 董事长兼总经理 熊慧 董事会秘书兼财务总监 李彦 独立董事 袁学伟 参与单位名称 及人员姓名 通过网络互动平台参与公司 2023 年度业绩说明会的投资者 时间 2024 年 4 月 25 日 15:00-16:00 地点 网上业绩说明会 形式 ☐现场 网上 ☐电话会议 投资者关系活 动主要内容介 绍 1、请领导介绍下公司的业务结构以及未来核心业务的发展规划， 谢谢！ 尊敬的投资者,您好。公司主营业务为体外诊断产品的研发、生产、 销售及科研、主要为白血病、淋巴瘤、实体瘤和传染病患者提供基因及 抗原的精准检测，为疾病诊断、风险评估、疾病分型、靶向药物选择和 疗效监测等个体化治疗方案的制定提供依据。2023 年，公司实现营业收 入 25,821.13 万元，其中白血病分子检测试剂盒收入 14,275.73 万元，同 比上升 11.88% ...

公司研究 点评： 营业收入有所下滑，肿瘤相关核心业务稳步增长：2023 年公司实现营收 2.58 亿 元（YOY-39.14%），实现归母净利润 793.07 万元（YOY-80.41%），实现扣非 归母净利润 369.52 万元（YOY-89.00%）。2023 年公司营业收入同比下降主要 系非核心检测业务收入下降较多，而肿瘤相关核心业务收入同比增长 17.22%； 归母净利润同比下降主要系检测业务收入大幅下降，同时累计折旧、人员等固定 成本增加使得期间费用较上年略有上升。 科技研发创新驱动发展，创新产品入围奖项：2023 年公司研发投入 6979.93 万 元，同比增长 8.34%，占营业收入 27.03%。截至 2023 年底，公司共取得 61 项专利授权，其中发明专利 52 项，实用新型专利 8 项，外观设计专利 1 项，并 于 2023 年新增 6 项发明专利，公司研发投入持续增加，多项产品荣获行业创新 奖项。2023 年 4 月，公司研发的人 MET 基因扩增检测试剂盒入围"肿瘤标志物 十大创新技术/产品"。2023 年 8 月，全资子公司源奇生物和瑞金医院联合开发 的"弥漫大 B 细胞淋巴瘤相关 ...

Financial Performance - The company reported a net profit for the first three quarters of 2023, with the cash dividend amounting to 126.77% of the annual net profit attributable to the parent company[12]. - The company's operating revenue for 2023 was ¥258,211,314.47, a decrease of 39.14% compared to ¥424,298,139.43 in 2022[32]. - Net profit attributable to shareholders for 2023 was ¥7,930,692.32, down 80.41% from ¥40,473,558.80 in 2022[32]. - The net profit after deducting non-recurring gains and losses was ¥3,695,202.93, a decline of 89.00% compared to ¥33,599,142.58 in 2022[32]. - The net cash flow from operating activities was ¥45,096,083.99, a decrease of 38.28% from ¥73,068,987.33 in 2022[32]. - The basic earnings per share for 2023 was ¥0.14, down 80.82% from ¥0.73 in 2022[32]. - The diluted earnings per share also decreased to ¥0.14, reflecting an 80.82% decline compared to ¥0.73 in 2022[32]. - The weighted average return on equity was 0.84%, a decrease of 3.59 percentage points from 4.43% in 2022[32]. - The total assets at the end of 2023 were ¥1,044,159,929.12, down 3.66% from ¥1,083,867,930.32 at the end of 2022[32]. - The net assets attributable to shareholders increased slightly to ¥945,776,279.95, a 0.95% increase from ¥936,895,942.58 at the end of 2022[32]. Dividend Policy - The company plans to distribute a cash dividend of 1.80 CNY per 10 shares, totaling approximately 10,054,061.28 CNY, which represents 53.40% of the net profit attributable to the parent company for the first three quarters of 2023[10]. - The proposed cash dividend for the fiscal year 2023 will not be distributed, as the company aims to retain earnings for future R&D and fixed asset investments[12]. - The company has not proposed any capital reserve transfers or stock dividends for the fiscal year 2023[12]. Research and Development - The company emphasizes its commitment to "precision medicine" and aims to enhance its core competitiveness through increased R&D investment[8]. - Research and development investments have increased by 40%, focusing on advanced molecular diagnostic technologies[23]. - The company's R&D expenditure as a percentage of operating revenue increased to 27.03%, up 11.85 percentage points from 15.18% in 2022[33]. - The total R&D investment for the year is approximately 69.8 million yuan, an increase of 8.34% from the previous year, with R&D expenses accounting for 27.03% of operating revenue, up 11.85 percentage points[174]. - The R&D personnel count has increased to 99, representing 19.76% of the total workforce, up from 15.90% in the previous period[184]. - The company has achieved significant milestones in its projects, such as obtaining regulatory approvals and completing clinical trials for multiple testing kits[180]. - The company has established an AI intelligent database tailored for the Chinese population, analyzing over 10,000 patient data points to optimize treatment plans for patients with poor prognosis[188]. Market Performance and Growth - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB, representing a year-over-year growth of 25%[23]. - User data showed an increase in active users, reaching 500,000, which is a 30% increase compared to the previous year[23]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 20% to 1.44 billion RMB[23]. - New product launches are expected to contribute an additional 200 million RMB in revenue, with a focus on innovative diagnostic solutions[23]. - The company is expanding its market presence, targeting an increase in market share by 15% in the next year through strategic partnerships[23]. Product Development and Innovation - The company has 13 Class III registration products currently under application, which may lead to increased costs for market promotion upon successful registration[8]. - The company is exploring potential acquisitions to enhance its product portfolio and market reach, with a budget of 300 million RMB allocated for this purpose[23]. - The company is in the process of obtaining medical device certifications for several new products, including the BCR-ABL fusion gene quantitative detection kit[59]. - The company has received regulatory approval for multiple gene mutation detection kits, including AML-related and diffuse large B lymphoma tests, currently in clinical trial phases[62]. - The company is developing a predictive model for early lung cancer diagnosis based on DNA methylation of seven related genes, with findings accepted for publication[80]. Operational Efficiency - The company has experienced an increase in fixed costs due to fixed asset additions and personnel restructuring[8]. - A new strategic initiative is being implemented to streamline operations, expected to reduce operational costs by 10% over the next year[23]. - The company has implemented an automated laboratory system capable of processing up to 20,000 tests daily, with report generation in under 10 minutes[85]. Risk Management - The company acknowledges potential risks related to its future plans and development strategies, advising investors to be cautious[14]. - The company has not engaged in any non-operational fund occupation by controlling shareholders or related parties[15]. Collaborations and Partnerships - The company is collaborating with Beijing University to establish a joint laboratory focusing on blood system, solid tumors, and aging diseases, aiming to innovate in precision medicine through big data and AI algorithms[66]. - The company collaborates with top hospitals, including Ruijin Hospital and Peking Union Medical College Hospital, enhancing its clinical cooperation and brand recognition[200]. Intellectual Property and Certifications - The company has obtained 10 medical device diagnostic reagent products registered with the drug supervision authority, including 3 Class II and 7 Class I products as of December 31, 2023[105]. - The company has received 61 patent authorizations, including 52 invention patents, with 11 new applications for invention patents during the year[169]. - The company has a total of 203 intellectual property rights, including 96 software copyrights and 61 patents, reflecting its strong focus on innovation[173].

上海睿昂基因科技股份有限公司 年度募集资金存放与使用情况鉴证报告 中国抗州市线江新城新业路8号UDC时代大厦A座5-8层、12层、23层 Eloors 5-8, 12 and 23, Block A, UDC Times Building; No. 8 Xinye Road, Qianjiang New City, Hangzhou. Tel. 0571-88879999 Fax. 0571-88879000 www.zhcpa.cn ■ 景 | 页 次 | | | --- | --- | | 一、年度募集资金存放与使用情况鉴证报告 | 1-3 | | 二、上海睿昂基因科技股份有限公司关于 2023年度募集资金 IN THE RESEMBLE CANNO CONS IN CHASTRACT | | | | | 中国抗州市钱江新城新业路8号UDC时代大厦A座5-8层、12层、23层 Floors 5-8, 12 and 23, Block A, UDC Times Building, No. 8 Xinye Road, Qianjiang New City, Hangzhou. Tol. 0571-888799 ...

证券代码：688217 证券简称：睿昂基因 公告编号：2024-023 上海睿昂基因科技股份有限公司 关于修订《公司章程》及部分内部管理制度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责 任。 上海睿昂基因科技股份有限公司（以下简称"公司"）于 2024 年 4 月 15 日 召开了第二届董事会第二十三次会议，审议通过了《关于修订<公司章程>的议案》 及《关于修订公司部分内部管理制度的议案》。现将有关情况公告如下： 上述事项尚需提交公司股东大会审议，公司董事会同时提请股东大会授权公 司管理层或其授权代表办理工商变更登记、章程备案等相关事宜。上述变更以上 海市市场监督管理局最终核准的内容为准。 二、修订公司部分内部管理制度的相关情况 根据《中华人民共和国公司法》《上市公司章程指引》《上海证券交易所 科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号 ——规范运作》《上市公司独立董事管理办法》等相关法律、法规和规范性文 件的要求，并结合公司的实际情况，公司拟对《独立董事制度》《关联交易管 理制度》《董 ...

国泰君安证券股份有限公司 关于上海睿昂基因科技股份有限公司 2023 年度募集资金存放与使用情况的专项核查意见 国泰君安证券股份有限公司（以下简称"国泰君安"、"保荐机构"）作为承 接上海睿昂基因科技股份有限公司（以下简称"公司"、"上市公司"、"睿昂基因"） 首次公开发行股票并在科创板上市持续督导工作的保荐机构，根据《上市公司监 管指引第 2 号——上市公司募集资金管理和使用的监管要求》《上海证券交易所 科创板股票上市规则》《上海证券交易所上市公司自律监管指引第 1 号——规范 运作》《科创板上市公司持续监管办法》等法律法规和规范性文件的要求，对睿 昂基因 2023 年度募集资金存放和使用情况进行了核查，核查情况及核查意见如 下： 一、募集资金基本情况 （一）实际募集资金金额、资金到位时间 经中国证券监督管理委员会 2021 年 4 月 6 日出具的《关于同意上海睿昂基 因科技股份有限公司首次公开发行股票注册的批复》（证监许可〔2021〕1126 号） 同意注册，并经上海证券交易所同意，公司首次公开发行人民币普通股（A 股） 1,390.00 万股，发行价为每股人民币 18.42 元，共计募集资金总额为人民 ...